| CUSTOMERS |
CUSTOMERS |
90%
|
For the fiscal year ended September 30, 2022, two customers represented approximately 11% and 11% of the sales of the WFOE and the VIE and its subsidiaries, respectively. |
| AHANZHAI-DEVELOPMENT-LIMITED |
AHANZHAI-DEVELOPMENT-LIMITED |
62%
|
diaries face risks related to natural disasters, extreme weather conditions, health epidemics and other catastrophic incidents, which could significantly disrupt their operations and negatively affec… |
| CHENGDU-CO-LTD |
CHENGDU-CO-LTD |
62%
|
NOTE 1 – ORGANIZATION AND DESCRIPTION OF BUSINESS Qilian International Holding Group Limited (“Qilian International”, or “the Company”) is a Cayman Islands exempted company incorporated on February 7… |
| CHENGDU-QILIANSHAN-BIOTECHNOLOGY-CO |
CHENGDU-QILIANSHAN-BIOTECHNOLOGY-CO |
62%
|
n technology and manufacturing facilities, Gansu QLS’s production capacity of oxytetracycline has reached its industrial upper limit. After thorough research and investigation, the R&D department of … |
| CHENGDU-QILIANSHAN-BIOTECHNOLOGY-CO-LTD |
CHENGDU-QILIANSHAN-BIOTECHNOLOGY-CO-LTD |
62%
|
n technology and manufacturing facilities, Gansu QLS’s production capacity of oxytetracycline has reached its industrial upper limit. After thorough research and investigation, the R&D department of … |
| CHIFENG-PHARMACEUTICAL-CO-LTD |
CHIFENG-PHARMACEUTICAL-CO-LTD |
62%
|
raw materials that are scarce, and the raw materials used in general are readily available from a wide range of local sources. Accordingly, the WFOE and the VIE and its subsidiaries do not have any c… |
| GANSU-QILIANSHAN-PHARMACEUTICAL-CO-LTD |
GANSU-QILIANSHAN-PHARMACEUTICAL-CO-LTD |
62%
|
NOTE 1 – ORGANIZATION AND DESCRIPTION OF BUSINESS Qilian International Holding Group Limited (“Qilian International”, or “the Company”) is a Cayman Islands exempted company incorporated on February 7… |
| HAINAN-PHARMACEUTICAL-FACTORY-CO-LTD |
HAINAN-PHARMACEUTICAL-FACTORY-CO-LTD |
62%
|
raw materials that are scarce, and the raw materials used in general are readily available from a wide range of local sources. Accordingly, the WFOE and the VIE and its subsidiaries do not have any c… |
| HEBEI-SHENGXUE-DACHENG-PHARMACEUTICAL-CO-LTD |
HEBEI-SHENGXUE-DACHENG-PHARMACEUTICAL-CO-LTD |
62%
|
raw materials that are scarce, and the raw materials used in general are readily available from a wide range of local sources. Accordingly, the WFOE and the VIE and its subsidiaries do not have any c… |
| HOLDER-ADDRESS-LEGAL-USE-METERS-GANSU-QILIANSHAN |
HOLDER-ADDRESS-LEGAL-USE-METERS-GANSU-QILIANSHAN |
62%
|
n technology and manufacturing facilities, Gansu QLS’s production capacity of oxytetracycline has reached its industrial upper limit. After thorough research and investigation, the R&D department of … |
| HUNAN-JIANLANG-PHARMACEUTICAL-CO-LTD |
HUNAN-JIANLANG-PHARMACEUTICAL-CO-LTD |
62%
|
raw materials that are scarce, and the raw materials used in general are readily available from a wide range of local sources. Accordingly, the WFOE and the VIE and its subsidiaries do not have any c… |
| JIANGXI-PHARMACEUTICAL-CO-LTD |
JIANGXI-PHARMACEUTICAL-CO-LTD |
62%
|
raw materials that are scarce, and the raw materials used in general are readily available from a wide range of local sources. Accordingly, the WFOE and the VIE and its subsidiaries do not have any c… |
| KUNMING-PHARMACEUTICAL-GROUP-CO-LTD |
KUNMING-PHARMACEUTICAL-GROUP-CO-LTD |
62%
|
raw materials that are scarce, and the raw materials used in general are readily available from a wide range of local sources. Accordingly, the WFOE and the VIE and its subsidiaries do not have any c… |
| LX-MANAGEMENT-COMPANY-LIMITED |
LX-MANAGEMENT-COMPANY-LIMITED |
62%
|
diaries face risks related to natural disasters, extreme weather conditions, health epidemics and other catastrophic incidents, which could significantly disrupt their operations and negatively affec… |
| MR-ZHANCHANG-XIN-CHINA-NATIONAL-PETROLEUM-CORPOR |
MR-ZHANCHANG-XIN-CHINA-NATIONAL-PETROLEUM-CORPOR |
62%
|
qualifications based on the following criteria, which include, but are not limited to: annual sales revenue, net profit, capitalization, production scales, competitive strength such as technological … |
| PRC-BGM-GROUP-LTD |
PRC-BGM-GROUP-LTD |
62%
|
diaries face risks related to natural disasters, extreme weather conditions, health epidemics and other catastrophic incidents, which could significantly disrupt their operations and negatively affec… |
| QILIAN-INTERNATIONAL-HOLDING-GROUP-LIMITED |
QILIAN-INTERNATIONAL-HOLDING-GROUP-LIMITED |
62%
|
diaries face risks related to natural disasters, extreme weather conditions, health epidemics and other catastrophic incidents, which could significantly disrupt their operations and negatively affec… |
| SHANXI-DATONG-TONGXING-ANTIBIOTICS-CO-LTD |
SHANXI-DATONG-TONGXING-ANTIBIOTICS-CO-LTD |
62%
|
raw materials that are scarce, and the raw materials used in general are readily available from a wide range of local sources. Accordingly, the WFOE and the VIE and its subsidiaries do not have any c… |
| USE-GANSU-QILIANSHAN-PHARMACEUTICAL-CO-LTD |
USE-GANSU-QILIANSHAN-PHARMACEUTICAL-CO-LTD |
62%
|
n technology and manufacturing facilities, Gansu QLS’s production capacity of oxytetracycline has reached its industrial upper limit. After thorough research and investigation, the R&D department of … |
| YUNNAN-BAIYAO-GROUP-CO-LTD |
YUNNAN-BAIYAO-GROUP-CO-LTD |
62%
|
raw materials that are scarce, and the raw materials used in general are readily available from a wide range of local sources. Accordingly, the WFOE and the VIE and its subsidiaries do not have any c… |
| ZH-CPA-LLC |
ZH-CPA-LLC |
62%
|
ents For the Year ended September 30, 2023 The VIE and Consolidated Parent Qilian HK WFOE subsidiaries Eliminat… |
